Lista de obras - Ahmed El-Shamy - Dominio Público Uruguay

A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

artículo científico publicado en 2015

CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway

artículo científico publicado en 2013

Detection of risky esophageal varices by two-dimensional ultrasound: when to perform endoscopy

artículo científico publicado en 2014

Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy

artículo científico publicado en 2011

Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics

artículo científico publicado en 2010

Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance

artículo científico publicado en 2013

Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients

artículo científico publicado en 2016

Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview

artículo científico

Mortality prediction of nonalcoholic patients presenting with upper gastrointestinal bleeding using data mining.

artículo científico publicado en 2014

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

artículo científico publicado en 2012

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

artículo científico publicado en 2012

Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.

artículo científico publicado en 2010

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

artículo científico publicado en 2013

Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis

artículo científico publicado en 2009

Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy

artículo científico publicado en 2011

Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma

artículo científico publicado en 2013

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load

artículo científico publicado en 2012

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load

artículo científico publicado en 2013

Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.

artículo científico publicado en 2010

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy

artículo científico publicado en 2012

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy

artículo científico publicado en 2011

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

artículo científico publicado en 2008

Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.

artículo científico publicado en 2008

Lista de obras de Ahmed El-Shamy

A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway

Detection of risky esophageal varices by two-dimensional ultrasound: when to perform endoscopy

Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy

Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics

Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance

Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients

Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview

Mortality prediction of nonalcoholic patients presenting with upper gastrointestinal bleeding using data mining.

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy

Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis

Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy

Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load

Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.